Game-changing COVID-19 tests are needed to fight the pandemic and Abbott has just developed one — a rapid antigen test called the BinaxNOWTM COVID-19 Ag Card — which received Emergency Use Authorization from the U.S. Food and Drug Administration.
In a recent CNBC op-ed, Abbott President and Chief Executive Officer Robert Ford examines how BinaxNOW and its complementary mobile app, called NAVICATM, could help make testing more accessible and give people some peace of mind amidst the uncertainty.
This story was originally published on September 04, 2020 and updated on June 03, 2022.
IMPORTANT SAFETY INFORMATION
The BinaxNOW™ COVID-19 tests have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization. They have been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
For serial testing, the BinaxNOW COVID-19 Antigen Tests should be performed twice over 3 days, at least 24 hours (and no more than 48 hours) apart. For symptomatic use, a single test can be used.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
FOLLOW ABBOTT